Abstract | BACKGROUND: METHODS: RESULTS: The mean serum levels of HAI-1 in patients with prostate cancer were significantly higher than those in patients with BPH. Furthermore, the serum HAI-1 levels in patients with distant metastasis and hormone resistant prostate cancer were significantly elevated compared with those in patients with organ-confined diseases. There were no significant differences in serum HAI-2 levels among prostate cancer subgroups according to clinical stage. Significantly elevated levels of HAI-1 were detected in 38 patients with prostate cancer before any treatment. CONCLUSIONS: HAI-1 may be a potential tumor marker for prostate cancer. Further studies in large groups of patients are needed to define the clinical value of HAI-1.
|
Authors | Osamu Nagakawa, Toshiya Yamagishi, Takuya Akashi, Kazuhiro Nagaike, Hideki Fuse |
Journal | The Prostate
(Prostate)
Vol. 66
Issue 5
Pg. 447-52
(Apr 01 2006)
ISSN: 0270-4137 [Print] United States |
PMID | 16353247
(Publication Type: Comparative Study, Journal Article)
|
Copyright | (c) 2005 Wiley-Liss, Inc. |
Chemical References |
- Biomarkers, Tumor
- Membrane Glycoproteins
- Proteinase Inhibitory Proteins, Secretory
- SPINT1 protein, human
- SPINT2 protein, human
- Trypsin Inhibitor, Kunitz Soybean
|
Topics |
- Biomarkers, Tumor
(blood)
- Enzyme-Linked Immunosorbent Assay
- Humans
- Male
- Membrane Glycoproteins
(blood)
- Neoplasm Staging
- Prostatic Neoplasms
(blood, pathology)
- Proteinase Inhibitory Proteins, Secretory
- Reference Values
- Reproducibility of Results
- Trypsin Inhibitor, Kunitz Soybean
(blood)
|